Aclarion Inc (ACON) Stock Price, Quote & News

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs whi...

Industry: Health Information Services

Sector: Healthcare

Phone: 833 275 2266

Website: www.aclarion.com

Address:

8181 Arista Place, Suite 100, Broomfield, United States

Imagiraffe Jul. 9 at 10:23 PM

$ACON she’s still holding the line. Cmon baby!

0 · Reply

tusambolo Jul. 9 at 9:15 PM

$ACON Can we just gap up to $15 so I can gtfo already?

1 · Reply

TrkDvr Jul. 9 at 7:47 PM

$ACON @StockRedBaron The fundamental flaw with your thesis is that you're apply logic. If that worked there would be no market as we'd all have made our bundle and quit out of boredom.

1 · Reply

TrkDvr Jul. 9 at 7:23 PM

$ACON Thanks @EpicComeback for the Wikipedia link to Dr Theodore. Clearly a highly qualified and recognized KOL in the field of back surgery. As the presenter of the Aclarion Spine Summit 2025 paper, I don't think we could have wished for anyone more qualified for the task

0 · Reply

EpicComeback Jul. 9 at 7:18 PM

$ACON give me $11,000 per share.

0 · Reply

EpicComeback Jul. 9 at 5:31 PM

$ACON this is not some Jabroni leading the trial https://en.wikipedia.org/wiki/Nicholas_Theodore

0 · Reply

StockRedBaron Jul. 9 at 4:29 PM

$DIS $ACON So on CNBC, they just said "Disney is not horribly expensive" Let's look: $121/sh $57.93 BV with $3.26 per share in cash. OK, now Aclarion: $7.39/sh $38.10/sh based on the newly announced $32/per share in cash, $32 cash ps, almost 10x DISNEY'S CASH per share....that's $79.63/ sh using Disney's metrics...which are quite low right now, btw.

0 · Reply

amax777 Jul. 9 at 2:52 AM

$ACON just remember what you have! A company that is breaking ground into a huge total adjustable market. They also have zero competition with their technology! The opportunity is so insane! Let people sleep on it so we can still load up. The stock has also turned a corner. When we finally catch fire, we’ll snap up fast!

0 · Reply

amax777 Jul. 9 at 2:43 AM

$ACON every time she wants to cross that hump, it can’t quite make it. I know some are upset, but show some patience. We’re consolidating for now, but our time will come

0 · Reply

MarkeTimer Jul. 9 at 12:55 AM

$BCTX $ACON No Trust No Touch

0 · Reply

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

May 20, 2025, 6:00 AM EDT - 7 weeks ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 12, 2025, 7:34 AM EDT - 2 months ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Apr 29, 2025, 6:00 AM EDT - 2 months ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 23, 2025, 6:00 AM EDT - 2 months ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 6:00 AM EDT - 2 months ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 9, 2025, 7:00 AM EDT - 3 months ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 2, 2025, 6:00 AM EDT - 3 months ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Mar 31, 2025, 7:00 AM EDT - 3 months ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 13, 2025, 9:25 AM EDT - 4 months ago

Aclarion Provides Shareholder Update

Mar 6, 2025, 9:35 AM EST - 4 months ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 3, 2025, 6:00 AM EST - 4 months ago

Aclarion Announces First Commercial Agreement with Scripps Health

Feb 20, 2025, 6:00 AM EST - 4 months ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 11, 2025, 7:58 AM EST - 5 months ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 6, 2025, 7:23 AM EST - 5 months ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 4, 2025, 7:23 AM EST - 5 months ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Nov 21, 2024, 8:00 AM EST - 8 months ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 14, 2024, 5:00 PM EST - 8 months ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Oct 10, 2024, 7:00 AM EDT - 9 months ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 6:57 AM EDT - 10 months ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 13, 2024, 8:30 AM EDT - 10 months ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 12, 2024, 6:57 AM EDT - 10 months ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 10, 2024, 6:57 AM EDT - 10 months ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 5, 2024, 6:57 AM EDT - 10 months ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aug 29, 2024, 6:57 AM EDT - 11 months ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 21, 2024, 7:57 AM EDT - 11 months ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 15, 2024, 9:48 AM EDT - 11 months ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 8:08 AM EDT - 11 months ago

Aclarion Announces First Commercial Agreement in Michigan

Aug 13, 2024, 9:07 AM EDT - 11 months ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 1 year ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Apr 25, 2024, 9:14 AM EDT - 1 year ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Feb 27, 2024, 3:22 PM EST - 1 year ago

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 1 year ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 5, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Jan 22, 2024, 8:00 AM EST - 1 year ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Nov 27, 2023, 8:00 AM EST - 1 year ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 6, 2023, 8:00 AM EST - 1 year ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Oct 25, 2023, 8:30 AM EDT - 1 year ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 24, 2023, 8:45 AM EDT - 1 year ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 23, 2023, 7:00 AM EDT - 1 year ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aug 25, 2023, 4:10 PM EDT - 2 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Jun 14, 2023, 11:27 AM EDT - 2 years ago

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Jun 8, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

May 30, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

May 23, 2023, 7:30 AM EDT - 2 years ago

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

May 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion, Inc. Announces Delayed 10-Q Filing

May 19, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts

Apr 28, 2023, 11:20 AM EDT - 2 years ago

Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023

Imagiraffe Jul. 9 at 10:23 PM

$ACON she’s still holding the line. Cmon baby!

0 · Reply

tusambolo Jul. 9 at 9:15 PM

$ACON Can we just gap up to $15 so I can gtfo already?

1 · Reply

TrkDvr Jul. 9 at 7:47 PM

$ACON @StockRedBaron The fundamental flaw with your thesis is that you're apply logic. If that worked there would be no market as we'd all have made our bundle and quit out of boredom.

1 · Reply

TrkDvr Jul. 9 at 7:23 PM

0 · Reply

EpicComeback Jul. 9 at 7:18 PM

$ACON give me $11,000 per share.

0 · Reply

EpicComeback Jul. 9 at 5:31 PM

$ACON this is not some Jabroni leading the trial https://en.wikipedia.org/wiki/Nicholas_Theodore

0 · Reply

StockRedBaron Jul. 9 at 4:29 PM

0 · Reply

amax777 Jul. 9 at 2:52 AM

0 · Reply

amax777 Jul. 9 at 2:43 AM

$ACON every time she wants to cross that hump, it can’t quite make it. I know some are upset, but show some patience. We’re consolidating for now, but our time will come

0 · Reply

MarkeTimer Jul. 9 at 12:55 AM

$BCTX $ACON No Trust No Touch

0 · Reply

Putnik Jul. 8 at 7:30 PM

$ACON send it to $30!

0 · Reply

amax777 Jul. 8 at 3:06 PM

$ACON holding strong so far 💪

0 · Reply

Imagiraffe Jul. 8 at 2:44 PM

$ACON get kickin baby. You know you want to!

0 · Reply

StockRedBaron Jul. 8 at 11:26 AM

$MULN $ACON So I woke up today in a "mathy" mood, I see Mullen at .27,--near ATL,BTW--& wanted to use this SP vs BV to show just how UNDERVALUED Aclarion is: Using the EXACT BVs on Finviz, Muln's overevaluation at 27 cents, placed on Aclarion would make Aclarion =$193,739.58/share. Right now. Today.

1 · Reply

amax777 Jul. 8 at 3:26 AM

$ACON good day too considering it was a down day in the market. She’s loading up like a spring to make a move! Still a great time to get in honestly. We’ve stabilized from the rocky start if before. It’s so obvious it’s clear skies from here

1 · Reply

amax777 Jul. 8 at 3:15 AM

$ACON like I said the good news just keeps piling up. We deserve to move above $8! Let’s get it!

0 · Reply

Imagiraffe Jul. 8 at 3:10 AM

$ACON this thing is gonna break loose. It’s only a matter of time! 🚀

0 · Reply

DipnRiptrader Jul. 7 at 9:45 PM

$ACON

0 · Reply

Enkky Jul. 7 at 9:16 PM

$ACON me love low volume stocks.

0 · Reply

DipnRiptrader Jul. 7 at 4:34 PM

$ACON Nice! Barely any volume tho.

0 · Reply

amax777 Jul. 7 at 4:02 PM

$ACON let’s goo! She wants to cross 8!!!

0 · Reply

StockRedBaron Jul. 7 at 3:11 PM

$ACON $7.96 now!!!

0 · Reply

Market Cap	4.34M
Revenue (ttm)	50,000.00
Net Income (ttm)	-6.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,980.00%
Debt to Equity Ratio	0.00

Volume	10,400
Avg Vol	20,972
Day's Range	N/A - N/A
Shares Out	582,000.00
Stochastic %K	51%
Beta	1.34
Analysts	Sell
Price Target	$20.00